[1] Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management[J]. Curr Opin Infect Dis, 2012, 25(1): 10-16. [2]中国艾滋病诊疗指南（2021年版）[J].中国艾滋病性病, 2021, 27(11): 1182-1201 [3] Karlsen TH, Sheron N, Zelber-Sagi S, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality[J]. Lancet, 2022, 399(10319): 61-116. [4] Jaquet A, Wandeler G, Nouaman M, et al. Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study[J]. J Int AIDS Soc, 2017, 19(1): 21424. [5] Amponsah-Dacosta E, Tamandjou Tchuem C, Anderson M, et al. Chronic hepatitis B-associated liver disease in the context of human immunodeficiency virus co-infection and underlying metabolic syndrome[J]. World J Virol, 2020, 9(5): 54–66. [6] Li F, Feng Y, Liu X, et al. HBV and HCV co-infection in Chinese newly diagnosed HIV+ subjects in 2015 and 2023: a cross-sectional study[J]. Pathogens, 2024, 13(5): 367.  [7] Liu D, Shen Y, Zhang R, et al. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China[J]. J Gastroenterol Hepatol, 2021, 36(6): 1670-1678.  [8]余娜苇,李梦晴,陈晨,等.初治HIV/AIDS患者非酒精性脂肪性肝病的患病率及影响因素分析[J].中国艾滋病性病,2024,30(06):607-611. [9] Yu N, Di X, Xia Z, et al. Prevalence and influencing factors of liver injury in naïve patients with HIV/AIDS in Nanjing from 2005 to 2022: Cross-sectional study[J]. Medicine (Baltimore), 2025, 104(22): e41261. [10] Sherman KE, Thomas DL. HIV and liver disease: a comprehensive update. Top Antivir Med[J], 2022, 30(4): 547-558. [11] Corcorran MA, Kim N. Chronic hepatitis B and HIV coinfection[J]. Top Antivir Med, 2023, 31(1): 14-22. [12] Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug-drug interactions in patients with HIV and metabolic syndrome[J]. Expert Opin Drug Metab Toxicol, 2024, 20(10): 953-965. [13] Mocroft A, Geressu A, Beguelin C, et al. The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe[J]. AIDS, 2023, 37(1): 91-103. [14]余娜苇,李梦晴,陈晨,等.初治HIV/AIDS患者非酒精性脂肪性肝病的患病率及影响因素分析[J].中国艾滋病性病,2024,30(06):607-611. [15] Kao E, Shinohara M, Feng M, et al. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes[J]. Hepatology, 2012, 56: 594-604. [16] Kolakowska A, Maresca AF, Collins IJ, et al. Update on Adverse Effects of HIV Integrase Inhibitors[J]. Curr Treat Options Infect Dis, 2019, 11(4): 372-387.  [17] Benedicto AM, Fuster-Martínez I, Tosca J, et al. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved[J]. Cells, 2021, 10(7): 1687. [18] Surial B, Béguelin C, Chave JP, et al. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study[J]. J Acquir Immune Defic Syndr, 2020, 85(2): 227-232. [19] Gunaratne SH, Taylor BS, Wilkin TJ, et al. CROI 2023: Advances in antiviral therapy in HIV and viral hepatitis[J]. Top Antivir Med, 2023, 31(3): 445–467. [20] Lok ASF. Toward a functional cure for hepatitis B[J]. Gut Liver, 2024, 18(4): 593–601. [21] Dugum M, O’Shea R. Hepatitis C virus: here comes all-oral treatment[J]. Cleve Clin J Med, 2014, 81(3): 159-172. [22] Chuo CY, Zachry W, de Boer M, et al. Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States[J]. Infect Dis Ther, 2025, 2025(7): e1192-5. [23] Bischoff J, Gu W, Schwarze-Zander C, et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART)[J]. EClinicalMedicine, 2021, 40: 101116. [24] Hardesty JE, McClain CJ. Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease[J]. Clin Liver Dis, 2024, 28(4): 731-745. [25]阮军,尹恒,寇国先,等.胸腺肽ɑ1联合还原型谷胱甘肽治疗酒精性肝病合并艾滋病的临床分析[J].中西医结合肝病杂志,2021,31(11):1005-1007. [26]陈苏,谢丽丽,崔慧娴,等.N-乙酰半胱氨酸对乙醇诱导张氏肝细胞损伤的保护作用[J].蚌埠医学院学报,2020,45(03):306-310. [27] Tang JX, Zhao D. Current status of liver transplantation for human immunodeficiency virus-infected patients in mainland China[J]. World J Gastroenterol, 2024, 30(14): 1958-1962. [28] Dogar AW, Ullah K, Uddin S, Ahmed HB. Liver Transplantation in HIV-Infected Patient[J]. J Coll Physicians Surg Pak, 2022, 32(12): 1635-1636.